

CORRECTED VERSION

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 September 2005 (01.09.2005)

PCT

(10) International Publication Number  
**WO 2005/080397 A3**

(51) International Patent Classification:  
C07D 487/00 (2006.01)

(21) International Application Number:  
PCT/US2005/005218

(22) International Filing Date:  
17 February 2005 (17.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/545,288 18 February 2004 (18.02.2004) US  
60/545,580 19 February 2004 (19.02.2004) US

(71) Applicants (for all designated States except US): AS-  
TRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).  
NPS PHARMACEUTICALS, INC. [US/US]; 383 Col-  
orow Drive, Salt Lake City, UT 84108 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JOHANSSON,  
Martin [SE/SE]; c/o AstraZeneca R & D Headquarters,  
Global Intellectual Property, SE-151 85 Södertälje (SE).  
WENSSBO, David [SE/SE]; c/o AstraZeneca R & D  
Headquarters, Global Intellectual Property, SE-151 85  
Södertälje (SE). MINIDIS, Alexander [SE/SE]; c/o  
AstraZeneca R & D Headquarters, Global Intellectual  
Property, SE-151 85 Södertälje (SE). STAAF, Karin  
[SE/SE]; c/o AstraZeneca R & D Headquarters, Global  
Intellectual Property, SE-151 85 Södertälje (SE). KERS,  
Annika [SE/SE]; c/o AstraZeneca R & D Headquarters,  
Global Intellectual Property, SE-151 85 Södertälje (SE).  
EDWARDS, Louise [CA/CA]; c/o NPS Allelix Corp.,  
6850 Goreway Drive, Mississauga, Ontario L4V 1V7  
(CA). ISAAC, Methvin [CA/CA]; c/o NPS Allelix Corp.,  
6850 Goreway Drive, Mississauga, Ontario L4V 1V7  
(CA). STEFANAC, Tomislav [CA/CA]; c/o NPS Allelix  
Corp., 6850 Goreway Drive, Mississauga, Ontario L4V  
1V7 (CA). SLASSI, Abdelmalik [CA/CA]; c/o NPS  
Allelix Corp., 6850 Goreway Drive, Mississauga, Ontario

L4V 1V7 (CA). MCLEOD, Donald [US/US]; c/o NPS  
Pharmaceuticals, Inc., 383 Colorow Drive, Salt Lake City,  
UT 84108 (US). XIN, Tao [CA/CA]; 10 Comoq Avenue,  
Woodbridge, Ontario L4H 2B1 (CA).

(74) Agents: MEIKLE, Andrew, Duff et al.; Birch, Stewart,  
Kolasch & Birch, LLP, 8110 Gatehouse Road, Suite 100  
East, P.O. Box 747, Falls Church, VA 22040-0747 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(88) Date of publication of the international search report:  
22 December 2005

(48) Date of publication of this corrected version:  
22 June 2006

(15) Information about Correction:  
see PCT Gazette No. 25/2006 of 22 June 2006

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC RECEPTOR ANTAGONISTS  
FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS



(57) Abstract: The present invention is directed to  
compounds of formula (I); wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ ,  $X^6$ ,  
 $X^7$ ,  $X^8$ ,  $X^9$ ,  $X^{10}$ ,  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ , and  $n$  are as defined for formula  
I in the description. The invention also relates to processes for  
the preparation of the compounds and to new intermediates  
employed in the preparation, pharmaceutical compositions  
containing the compounds, and to the use of the compounds  
for treating gastrointestinal disorders.